“`html
A recent decision by a federal judge in Washington, D.C. has affirmed the exclusivity enjoyed by United Therapeutics Corp. for its lung disease treatment, Tyvaso, through May. The ruling supports the U.S. Food and Drug Administration’s position on withholding approval for competing products during this period.
According to the decision, this exclusivity enables United Therapeutics to retain its market edge for Tyvaso, which is used to treat pulmonary arterial hypertension. For additional details, you can access the full text of the ruling on Law360.
“`